Yikon Genomics
A professional service provider for reproductive and cancer genetic testing.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
CNY250m | Series D | ||
| Total Funding | 000k | ||
Related Content
Yikon Genomics specializes in providing advanced genomic solutions primarily for fertility clinics and oncology research. The company operates in the global healthcare market, offering a range of products and services that leverage its proprietary MALBAC (Multiple Annealing and Looping-Based Amplification Cycles) technology. This technology enables rapid and precise DNA analysis, which is crucial for pre-implantation genetic testing (PGT) and cancer diagnostics.
Yikon Genomics serves fertility clinics, research institutions, and healthcare providers. Its core products include PGTA ChromInst, PGTM ChromSwift, and MaReCs, which are designed to enhance the accuracy and speed of genetic testing. The company’s business model revolves around selling these specialized genomic testing kits and providing associated services. Revenue is generated through the sale of these kits and ongoing service contracts with healthcare providers and research institutions.
The company’s market is highly specialized, focusing on fertility treatments and oncology, where precise genetic information can significantly impact treatment outcomes. Yikon Genomics differentiates itself through its innovative MALBAC technology, which allows for the amplification of single-cell DNA, making it possible to conduct comprehensive genetic analyses quickly and accurately.
Keywords: Genomic solutions, fertility clinics, oncology research, DNA analysis, MALBAC technology, pre-implantation genetic testing, cancer diagnostics, healthcare market, genetic testing kits, single-cell DNA.